Banco de Sabadell S.A lessened its stake in Humana Inc (NYSE:HUM) by 16.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 26,401 shares of the insurance provider’s stock after selling 5,343 shares during the period. Humana comprises approximately 1.0% of Banco de Sabadell S.A’s portfolio, making the stock its 21st largest position. Banco de Sabadell S.A’s holdings in Humana were worth $7,850,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. FMR LLC increased its holdings in Humana by 12.7% in the 2nd quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after purchasing an additional 1,374,030 shares during the last quarter. BlackRock Inc. increased its holdings in Humana by 1.7% in the 1st quarter. BlackRock Inc. now owns 12,186,387 shares of the insurance provider’s stock valued at $3,276,068,000 after purchasing an additional 198,588 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Humana by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,564,251 shares of the insurance provider’s stock valued at $420,503,000 after purchasing an additional 11,915 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Humana by 7.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,324,681 shares of the insurance provider’s stock valued at $394,262,000 after purchasing an additional 93,021 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in Humana by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 768,245 shares of the insurance provider’s stock valued at $228,653,000 after purchasing an additional 26,303 shares during the last quarter. Hedge funds and other institutional investors own 93.00% of the company’s stock.

Shares of HUM stock opened at $332.88 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43. The firm has a market cap of $46.44 billion, a P/E ratio of 28.43, a PEG ratio of 1.68 and a beta of 0.96. Humana Inc has a 12 month low of $231.90 and a 12 month high of $337.56.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.17. The firm had revenue of $14.26 billion during the quarter, compared to the consensus estimate of $14.16 billion. Humana had a net margin of 2.48% and a return on equity of 17.43%. During the same quarter in the previous year, the firm posted $3.49 earnings per share. sell-side analysts anticipate that Humana Inc will post 14.18 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 26th. Investors of record on Friday, September 28th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Thursday, September 27th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.60%. Humana’s payout ratio is currently 17.08%.

Several research firms have commented on HUM. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Wednesday, July 4th. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $326.00 price target for the company in a research note on Monday, May 21st. BMO Capital Markets boosted their price target on shares of Humana from $328.00 to $355.00 and gave the stock an “outperform” rating in a research note on Monday, June 25th. SunTrust Banks restated a “hold” rating and issued a $350.00 price target on shares of Humana in a research note on Thursday, August 2nd. Finally, Piper Jaffray Companies boosted their price target on shares of Humana from $326.00 to $350.00 and gave the stock an “overweight” rating in a research note on Friday, July 6th. Six investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $328.94.

In related news, insider Elizabeth D. Bierbower sold 3,092 shares of the business’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the completion of the transaction, the insider now owns 14,289 shares in the company, valued at $4,715,370. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Timothy Alan Wheatley sold 11,468 shares of the business’s stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $299.40, for a total transaction of $3,433,519.20. Following the transaction, the insider now owns 3,889 shares of the company’s stock, valued at approximately $1,164,366.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 61,213 shares of company stock valued at $19,081,052. Insiders own 0.60% of the company’s stock.

Humana Profile

Humana Inc is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.

Featured Article: Market Capitalization and Individual Investors

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.